cefixime has been researched along with vancomycin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dean, PC; Farquhar, DS; Gremse, DA | 1 |
| Ohsawa, R; Okazaki, N; Sata, S; Suzuki, R; Wada, A; Watanabe, H; Watanabe, Y; Yamai, S | 1 |
| Aleksic, S; Bockemühl, J; Lehmacher, A; Meier, H | 1 |
| Bettelheim, KA; Djordjevic, SP; Hornitzky, MA | 1 |
| Edge, V; Foster, G; Graham, DJ; Gunn, GJ; Hopkins, GF; Knight, HI; Synge, BA; Ternent, HE; Thomson-Carter, F | 1 |
| Arakawa, S; Deguchi, T; Egashira, T; Fujime, M; Fujita, K; Fukuhara, Y; Furuya, N; Hirakata, Y; Hirose, T; Igari, J; Imafuku, Y; Ishibashi, K; Ishihara, S; Kamidono, S; Kitamura, M; Kobayashi, Y; Kohno, S; Kondo, A; Konishi, T; Kumamoto, Y; Kumon, H; Kunishima, Y; Matsuda, J; Matsuda, S; Matsukawa, M; Matsumoto, T; Monden, K; Murai, M; Muratani, T; Naito, S; Nakano, M; Oguri, T; Oka, T; Ooe, H; Sato, S; Shigeta, S; Suzutani, T; Tsukamoto, T; Uchida, H; Watanabe, K; Yamaguchi, K; Yamaguti, O; Yoshida, H | 1 |
| Baylis, CL | 1 |
| Gurnani, B; Kannusamy, V; Kaur, K; Yadalla, D | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Al-Qawasmeh, RA; Al-Tel, TH | 1 |
| Bhat, HR; Kumawat, MK; Singh, B; Singh, UP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cefixime and vancomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for cefixime and vancomycin
| Article | Year |
|---|---|
Cefixime and antibiotic-associated colitis.
Topics: Cefixime; Cefotaxime; Child; Child, Preschool; Enterocolitis, Pseudomembranous; Female; Humans; Male; Vancomycin | 1994 |
[Studies on enrichment broth for verotoxin-producing Escherichia coli (VTEC) O157].
Topics: Aeromonas; Anti-Bacterial Agents; Bacterial Toxins; Bacteriological Techniques; Cefixime; Cefotaxime; Cephalosporins; Culture Media; Drug Resistance, Microbial; Escherichia coli O157; Novobiocin; Pseudomonas; Shiga Toxin 1; Tellurium; Temperature; Vancomycin | 1997 |
Detection of hemolysin variants of Shiga toxin-producing Escherichia coli by PCR and culture on vancomycin-cefixime-cefsulodin blood agar.
Topics: Bacterial Toxins; Base Sequence; Blood; Cefixime; Cefotaxime; Cefsulodin; Culture Media; Escherichia coli; Feces; Food Microbiology; Hemolysin Proteins; Humans; Molecular Sequence Data; Sequence Alignment; Shiga Toxins; Vancomycin | 1998 |
The detection of Shiga toxin-producing Escherichia coli in diagnostic bovine faecal samples using vancomycin-cefixime-cefsulodin blood agar and PCR.
Topics: Adhesins, Bacterial; Animals; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacteriological Techniques; Carrier Proteins; Cattle; Cattle Diseases; Cefixime; Cefsulodin; Culture Media; Diarrhea; Escherichia coli; Escherichia coli Proteins; Feces; Hemolysin Proteins; Polymerase Chain Reaction; Serotyping; Shiga Toxin 1; Shiga Toxin 2; Vancomycin; Virulence | 2001 |
A comparison of two pre-enrichment media prior to immunomagnetic separation for the isolation of E. coli O157 from bovine faeces.
Topics: Animals; Anti-Bacterial Agents; Bacteriological Techniques; Bacteriophage Typing; Cattle; Cefixime; Cefsulodin; Culture Media; Disease Reservoirs; Escherichia coli O157; Feces; Immunomagnetic Separation; Sensitivity and Specificity; Vancomycin | 2003 |
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Topics: Aminoglycosides; Ampicillin; Anti-Infective Agents; Aztreonam; Cefixime; Cefozopran; Cefpirome; Cefpodoxime; Ceftizoxime; Cephalosporins; Dibekacin; Drug Resistance, Bacterial; Enterococcus faecalis; Escherichia coli; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Proteus mirabilis; Pseudomonas aeruginosa; Quinolones; Serratia marcescens; Staphylococcus aureus; Thienamycins; Urinary Tract Infections; Vancomycin | 2006 |
Growth of pure cultures of Verocytotoxin-producing Escherichia coli in a range of enrichment media.
Topics: Cefixime; Cefsulodin; Colony Count, Microbial; Culture Media; Electric Impedance; Escherichia coli O157; Nephelometry and Turbidimetry; Novobiocin; Temperature; Vancomycin | 2008 |
A tale of orbital cellulitis and retinopathy of prematurity in an infant: First case report.
Topics: Cefixime; Child; Female; Gestational Age; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Moxifloxacin; Ophthalmic Solutions; Orbital Cellulitis; Retina; Retinopathy of Prematurity; Vancomycin | 2022 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.
Topics: Anti-Bacterial Agents; Cell Proliferation; Gram-Negative Bacteria; Gram-Positive Bacteria; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Pyridines; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2010 |
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.
Topics: Anti-Bacterial Agents; Biofilms; Dose-Response Relationship, Drug; Drug Discovery; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Pyrazoles; Structure-Activity Relationship; Triazines | 2014 |